Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Inclusion criteria

• Recently diagnosed type 2 diabetes (within 3 years) on diet or IGT
• Fasting triglyceride levels >140 and < 400 mg/dl and values varying less than 35% between two screening measurements
• Normal liver function tests and white blood cell count

Exclusion criteria

• Type 2 Diabetes for > 3 years or HbA1c ≥ 7.5
• Known or suspected Type 1 Diabetes
• Any diabetes medications in the past 3 weeks, TZD in the prior 3 months or prior regular use of insulin
• Creatinine > 2.0 mg/dl or other evidence of active kidney disease
• Hepatic enzyme elevation > 2x normal
• Known Nonalcoholic Fatty Liver Disease
• Malabsorption of fat or other nutrients, severe lactose intolerance or other significant gastrointestinal or pancreatic problems
• Recent history of nausea or vomiting
• Acute bacterial or viral illness or evidence of other active infection in the past 4 weeks
• A prior cardiovascular event, stable or unstable angina or other major illness in the past 6 months
• Current regular use of anti-inflammatory medications or antioxidants, including over the counter medications and high dose salicylates (>1 g/day)
• Any lipid lowering therapy in the prior 3 weeks other than a statin medication. Subjects receiving a statin medication must be on a stable dose for at least 2 months prior to participation.